Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the impact of vitamins, stress reduction, and appropriate shampoo on hair health, with the original poster noting slight improvements after two months of using vitamins B5, B6, zinc, and a suitable shampoo. Many users express skepticism about the effectiveness of vitamins for hair loss unless there is a deficiency, emphasizing the importance of addressing DHT and considering 5AR inhibitors.

Finasteride can cause dry eyes and vision issues due to its impact on the meibomian glands. Users have mixed experiences, with some experiencing eye discomfort and others having no side effects.

A user's experience with hair loss treatments, including Finasteride, Minoxidil, Nizoral Shampoo, Rosemary Oil, Vitamin D, Biotin, Vitamin C, Zinc and Dermarolling, that have not been successful over the past 14 months. Other users gave advice on how to cope with the issue, such as exercising, changing mindset, and shaving their head.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

Biotin can cause cystic acne for some users, and it's advised to stop using it if this occurs. For hair loss, finasteride and dutasteride are recommended, but a dermatologist should be consulted.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

CHK-Cu (copper peptide) and C-60 (branched carbon chain) are discussed as potentially more effective than minoxidil for hair regrowth. Some users are skeptical about the claim that DHT isn't the root cause of hair loss, and others are trying these products to see if they work.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

Copper peptides are discussed as a potential treatment for hair loss, with various products and serums suggested, including those from Peptonix and The Ordinary. Some users express skepticism about the effectiveness and concentration of copper peptides in these products.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.